CTT Pharma Advances Toward Manufacturing and SEC Reporting Status with Patented Drug Delivery Technology
TL;DR
CTT Pharma's patented micelle technology offers a competitive edge in drug delivery, with manufacturing plans for 2026 and SEC reporting to attract more investors.
CTT Pharma will file an S-1 for funding, use capital for manufacturing, hire regulatory experts, and locate a production facility in Q1 2026.
CTT Pharma's technology aims to improve oral drug delivery, potentially enhancing healthcare accessibility and offering a smoking cessation alternative through a Johns Hopkins partnership.
CTT Pharma's scientific paper on micelle strip technology will be published on December 15, 2025, increasing visibility and scientific understanding.
Found this article helpful?
Share it with your network and spread the knowledge!
CTT Pharma CEO Ryan Khouri detailed the company's strategic initiatives in a letter to shareholders, emphasizing progress toward manufacturing and regulatory milestones for its patented micelle thin-film drug delivery technology. The company aims to bring micelle-encapsulated vitamin supplements and nicotine oral strips into production in 2026, leveraging capital from an upcoming equity line to fund manufacturing setup.
Khouri stated that CTT is finalizing an S-1 filing to become an SEC reporting company, a move expected to enhance transparency and attract a broader investor base. While targeting completion by the end of 2025, the timeline may extend into early 2026. The CEO emphasized careful management of share dilution while utilizing the equity line capital for manufacturing infrastructure.
To support commercialization, CTT is hiring regulatory experts and a professional with experience in bringing products to market. The company is also securing a manufacturing facility, with plans to identify a building in the first quarter of 2026 and acquire necessary equipment. These efforts are independent of the pending NIH funding decision for clinical trials related to the company's partnership with Johns Hopkins University on smoking cessation alternatives.
Scientific validation of CTT's technology is advancing through a peer-reviewed manuscript accepted for publication on December 15, 2025. Co-authored by scientist Dr. Katharine Cole and founder Dr. Pankaj Modi, the paper reviews current research in micelle-based oral dissolvable strip technology. Khouri noted this publication will increase visibility and understanding of the platform among shareholders, potential partners, and the scientific community.
The company is strengthening its patent portfolio and plans a conference call in the first quarter to discuss progress. Shareholders can access the original release on www.newmediawire.com for additional details. With capital secured, team expansion underway, and regulatory pathways being defined, CTT is positioning itself to commercialize its innovative drug delivery technology while maintaining shareholder communication through upcoming updates.
Curated from NewMediaWire
